Is It Time To Reassess Illumina (ILMN) After Its Recent Share Price Volatility?

• For readers wondering whether Illumina at around US$126.63 is priced for opportunity or already reflects the current story, this article walks through what the share price might be implying about value.
• The stock has had a mixed run, with a 0.3% return over 7 days and a 4.7% decline over 30 days, set against a 54.7% gain over the past year and longer term declines of 43.6% over 3 years and 67.5% over 5 years.
• These moves have come as Illumina remains in focus for investors, following ongoing attention on its core DNA sequencing business and portfolio decisions that keep sentiment shifting. Recent headlines continue to frame the stock as a key name in genomics, which helps explain why the share price has been volatile over different time horizons.
• On Simply Wall St's valuation checks, Illumina scores 3 out of 6. The rest of this article will break that down using different valuation approaches and will also hint at a broader way to think about value that ties everything together at the end.

Illumina delivered 54.7% returns over the last year. See how this stacks up to the rest of the Life Sciences industry.

Approach 1: Illumina Discounted Cash Flow (DCF) Analysis

A DCF model estimates what a company might be worth by projecting its future cash flows and discounting them back to today at an appropriate rate. It is essentially asking what all of Illumina’s expected future cash generation could be worth in today’s dollars.

For Illumina, the latest twelve month Free Cash Flow is about $862.3 million. Using a 2 Stage Free Cash Flow to Equity model, analysts provide explicit projections out to 2029, with Simply Wall St extrapolating further based on those inputs. Within this framework, one of the reference points is a projected Free Cash Flow of $1,095 million in 2029, with intermediate annual figures between 2026 and 2035 used to build a cash flow curve over time.

When these cash flows are discounted back, the model arrives at an estimated intrinsic value of about US$148.97 per share. Against a current share price around US$126.63, this implies Illumina screens as roughly 15.0% undervalued on this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Illumina is undervalued by 15.0%. Track this in your watchlist or portfolio, or discover 63 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Illumina.

Approach 2: Illumina Price vs Earnings

For a business that is generating earnings, the P/E ratio is often a useful shorthand because it links what you are paying directly to the profits the company is producing today. It is one of the quickest ways to compare how the market is valuing those earnings across different companies.

What counts as a “normal” P/E depends on how fast earnings are expected to grow and how risky those earnings might be. Higher expected growth or lower perceived risk can support a higher multiple, while slower growth or higher risk usually point to a lower one.

Illumina currently trades on a P/E of 22.78x, compared with a Life Sciences industry average of about 30.36x and a peer group average of 33.40x. Simply Wall St’s Fair Ratio for Illumina is 19.87x. This Fair Ratio is a proprietary estimate of what a reasonable P/E could be for the company given factors like its earnings growth profile, profit margins, industry, market cap and specific risks. That makes it more tailored than a simple comparison with broad industry or peer averages, which do not adjust for those company specific drivers.

Compared with this Fair Ratio, Illumina’s current 22.78x P/E is higher, suggesting the shares look overvalued on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Illumina Narrative

Earlier the article mentioned that there is an even better way to understand valuation. Meet Narratives, a simple tool on Simply Wall St's Community page that lets you set out your story for Illumina, link it to your own revenue, earnings and margin assumptions, and see the fair value that falls out of those numbers. You can then compare that to the current market price to help assess whether the stock looks attractively or richly priced based on your view. The model automatically refreshes as new earnings, news or guidance arrive. For example, a bullish Illumina Narrative might lean closer to a fair value around US$156.51, while a cautious one could sit nearer US$75. This reflects how different investors can look at the same business, plug in different expectations and reach very different conclusions.

For Illumina, here are previews of two leading Illumina narratives:

🐂 Illumina Bull Case

Fair value: US$136.11

Implied discount to this fair value at US$126.63: about 7.0%

Analyst revenue growth assumption: 5.4% a year

• Analysts cite clinical genomics and next generation sequencing as key drivers of recurring consumables revenue and clearer earnings visibility.
• They also factor in product launches, multiomics expansion and cost control as supports for margins over time.
• This perspective uses a consensus price target of US$136.11, with revenue of US$5.1b and earnings of US$1.0b by 2029 and a 23.1x P/E, based on an 8.1% discount rate.

🐻 Illumina Bear Case

Fair value: US$88.35

Implied premium to this fair value at US$126.63: about 43.4%

Analyst revenue growth assumption: 4.4% a year

• Bearish analysts highlight competition, regulation, cost pressure and reliance on clinical customers as potential headwinds for growth and margins.
• This view assumes slower revenue growth, lower profit margins and a future P/E of 15.8x, discounted at about 8.1%.
• The implied fair value of US$88.35 is well below the current price, so this camp sees more downside risk if their earnings path occurs.

Do you think there's more to the story for Illumina? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com